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Abstract
The prophylactic capacity of the RUTIH vaccine, based on fragmented cells of Mycobacterium tuberculosis, has been
evaluated in respect to aerosol challenge with virulent bacilli. Subcutaneous vaccination significantly reduced viable
bacterial counts in both lungs and spleens of C57Bl mice, when challenged 4 weeks after vaccination. RUTIH protected the
spleen less than BCG. Following a 9 month vaccination-challenge interval, protection was observed for the lungs, but not for
the spleen. Survival of infected guinea pigs was prolonged by vaccination given 5 weeks before challenge. Inoculations of
RUTIH shortly after infection significantly reduced the viable bacterial counts in the lungs, when compared with infected
control mice. Thus, vaccination by RUTIH has potential for both the prophylaxis and immunotherapy of tuberculosis.
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Introduction
Despite the major efforts undertaken to eradicate tuberculosis
(TB), it remains a major health problem, with approximately 1.8
million deaths, 9 million incident cases and 13 million prevalent
cases worldwide every year [1]. One of the key priorities for
tuberculosis research involves focusing on therapeutic and
preventive strategies [2]. Multidrug resistance and co-infection
with HIV affect the dynamics of both the infection and the disease,
therefore both these factors need to be taken into account when
designing new strategies to combat TB [1].
In order to stop the spread of this infection, most recent
research has focused on designing new prophylactic vaccine
candidates with better safety and immunogenic profiles to either
boost BCG (by ameliorating its immunogenic profile and
prolonging its protection), or replace it [3]. As numerous different
aspects of TB need to be covered in order to achieve its final
eradication [3], the ‘‘perfect’’ approach would appear to involve a
single polyfunctional vaccine candidate that is able to prevent the
infection of healthy individuals whilst at the same preventing the
reactivation and reinfection of latently infected people.
The aim of the present project was to assess the protective
capacity of the RUTIH vaccine given either as prophylaxis, or soon
after the infection, i.e. before the onset of the infection induced
immune response.Primarily designed as a therapeutic agent to
shorten the chemotherapy treatment of latent tuberculosis infection
(LTBI), RUTIH is developed under good manufacturing practices
(GMP) in Badalona (Catalonia, Spain), by Archivel Farma [4].
The objectives of the present study were 1.- to determine the
prophylactic effects produced by this vaccine in mice: short and
long term; 2.- the prophylactic effect in guinea pigs and 3.- the
protective effect when given soon after infection in mice.
Results
Short-term prophylactic effect experiment
The effect of short-term vaccination on the bacillary load can be
seen in Figure 1. RUTIH vaccine reduced the bacillary load in
both lungs (0.58 log) and spleen (0.6 log) of mice, showing a
statistically significant protective effect when compared to the
control group (One-Way Anova, p,0.005). BCG appeared to be
more effective than RUTIH (reduction in lungs: 1.04 logs; and in
the spleen: 1.29), although the difference was only statistically
significant in spleen (One-Way Anova, p,0.005).
Long-term vaccination prophylactic effect experiment
The results of the long-term vaccination experiment (Figure 2)
show that every vaccination regimen had a protective effect in lung
of mice. The decrease of the bacillary load in lungs was 0.78 and
0.8 logs for RUTIH and BCG respectively. This effect was
statistically significant when compared to the control group (One-
Way Anova, p,0.005). In spleen the reduction was lower: 0,38
logs for RUTIH and 0.15 for BCG. No differences were
encountered between either the prophylactic regimens or the
boosting ones, although animals vaccinated with BCG and
boosted with RUTIH seemed to have better results than the other
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being statistically significantly in one of the two repetitions of the
experiment. As all animals were challenged nine months after the
first vaccination, the long-lasting protective effect in lung achieved
by both RUTIH and BCG is quite remarkable.
Short-term prophylactic effect in guinea pigs
The results obtained in the survival experiment, which was
ended at week 47 post-challenge, are presented in Figure 3. The
Kaplan-Meier Survival Analysis shows a notable increase in the
survival of the vaccinated animals, although only the BCG
vaccination showed a statistically significant difference with respect
to the control group.
Protective effect when vaccinating soon after the
infection
The results (Figure 4) showed that RUTI decreased the bacillary
load in mice lungs when given at day 4 (reduction of 0.53 logs) or
at day 4 plus 11 (reduction of 1.03 logs) post challenge in a
statistically significant way when compared to the infected and the
BCG-vaccinated groups (One-Way Anova, p,0.005). No statis-
tically significant differences where encountered in the spleen.
Discussion
Vaccination is known to be the most cost-effective intervention
to control TB, as explained elsewhere [5]. Indeed, the BCG
vaccine has proven to be a useful tool over many years and has led
to a reduction of the incidence of severe cases in infants. However,
this vaccine seems to have poor efficacy especially in non-endemic
countries, and systematic vaccination has been progressively
abandoned [6], although it is still needed in areas with a high-
prevalence of TB. Coinfection with HIV worsens the panorama as
HIV-positive children vaccinated with BCG are at risk of
developing a serious complication known as BCG disease
[7,8,9]. As those countries with the highest rates of tuberculosis
infection also have high rates of HIV infection, this is a serious
cause for concern [8]. Furthermore, the increasing incidence of
multidrug-resistant TB strains is also worrying. As a result, and in
order to develop a better vaccine, the last few years have been very
productive in terms of design of new vaccine candidates against
TB. Indeed, some of the 12 new vaccine candidates already
undergoing clinical trials have been designed as prophylactic
vaccines in order to replace BCG or to boost it, whereas others are
intended for use as therapeutic agents to accelerate or ameliorate
chemotherapy, [10,11]. These candidates are normally grouped
on the basis of their nature (recombinant live, viral vectored,
recombinant protein and other), although they can also be
grouped on the basis of the vaccination strategy in which they
were designed to be used (prime-boost, post-exposure, immuno-
Figure 1. Protection after a short-term vaccination in terms of
bacillary load obtained in tissues. The figure shows the reduction
of the bacillary load in the lungs and spleen of animals according to
their experimental group. The experimental groups are shown as
follows: black (unvaccinated animals, control group), white (BCG
vaccinated) and striped (RUTIH vaccinated). Significant differences
(p,0.05) obtained after the statistical analysis (One-Way Anova)
between groups are marked with an asterisk.
doi:10.1371/journal.pone.0020404.g001
Figure 2. Results of the long-term vaccination experiment. The
experimental groups are shown as follows: black (unvaccinated animals,
control group), white (BCG vaccinated), striped (RUTIH vaccinated),
chequered (BCG boosted with RUTIH) and with diamonds (RUTIH
boosted with RUTIH). Significant differences (p,0.05) between groups
are marked with an asterisk.
doi:10.1371/journal.pone.0020404.g002
Figure 3. Survival experiment in guinea pigs after short-term
vaccination. Data show the evolution of the protection given by the
vaccination. Only the BCG group demonstrated a significant difference
when compared with the control under the Kaplan-Meier Survival
Analysis.
doi:10.1371/journal.pone.0020404.g003
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approach as the clinical aspects of infection and disease are
different and the immunopathogenesis of each one is as-yet
unclear. Infected people also represent a big problem, both at a
public health level as a reservoir of disease and at an individual
level as 10% are susceptible to developing active TB. The ‘‘ideal’’
vaccine candidate would therefore be one which is able to prevent
infection in a healthy person, trigger an immune response that is
able to clear the infection in a recently exposed person, and to halt
infection by decreasing the bacillary burden, thereby preventing
reinfection and progress towards active disease, in a latently
infected person. The best approach may therefore be to explore all
the possibilities of these new candidates, as suggested recently [3]
and has already been partially done in cases such as MVA85A,
which has been evaluated in many different schedules and
populations [12].
RUTIH is a vaccine candidate which was primarily designed to
be included as an adjunctive to chemotherapy in an LTBI
therapeutic regimen in order to reduce its duration and improve
its efficacy. RUTIH is based on fragmented cells of M. tuberculosis,
with the product being pasteurized, lyophilized and liposomed to
allow better antigen presentation [4], and has demonstrated its
immunogenicity against antigens traditionally related to the
stationary phase of the bacilli (Rv 2031c, Rv 0934) [13]. The
safety and efficacy of this vaccine have been tested in numerous
experiments conducted in mice, guinea pigs, goats and minipigs,
and the vaccine finally entered clinical development in 2007
[14,15,16,17]. The phase 1 clinical trial (CT) proved it to be safe
and immunogenic, thus allowing RUTIH to be evaluated in the
context of a phase 2 CT, which began in South Africa at the
second half of 2010 [18].
In spite of the murine models being so different than humans,
mice were primary chosen as the best first screening to evaluate
the impact of the prophylaxis administration of RUTIH. At short-
term, both immunizations showed a statistically significant
decrease on the bacillary load of more than half a log (both in
lungs and spleen), less than the values usually reached using other
candidates [19], BCG achieving better results than RUTIH. The
effect of both immunizations on the bacillary load of lungs
remained and was even higher than at short term in the case of
RUTIH when challenging the mice 9 months after. In this long-
term experiment RUTIH proved to be as good as BCG. Adding a
boosting with RUTIH to BCG tended to increase this effect. As
expected from evidences obtained in previous studies using
RUTIH as a therapeutic agent, the boost with this vaccine
candidate did not provoke a necrotic Koch reaction [20,21].
Guinea-pigs were used in order to evaluate the impact of
vaccination on the animals’ survival, for their major susceptibility
to M.tuberculosis infection, as has been done in other studies [22]. In
this model, both RUTIH and BCG resulted in an increased
survival when compared to the unvaccinated control, although the
difference was only statistically significant for the BCG group,
something that we relate to the low number of animals included in
the study.
The results of RUTIH in the post-challenge experiments suggest
that it could be given to recently infected people, in particular in
those negative tuberculin skin test contacts of a tuberculosis index
case. This would be feasible as the normal policy (in some
countries like Spain) in these subjects is to provide chemoprophy-
laxis until retesting them with a tuberculin skin test (TST) two
months later. If the TST remains negative, the chemotherapy is
stopped, while being extended (up to 9 months) if the TST
converts and the infection is confirmed [23]. The fact that
protection is only achieved when RUTIH is administered at day 4
but not at day 11, suggests that it should be given as soon as
possible after the exposure. If not, the immune response is not
elicited quick enough to stop the bacillary load (i.e. in the case of
being administered only at day 11). Besides, a second dose at day
11 achieves better results, and we assume this is because of
boosting the immune response induced by the dose at day 4.
We believe that several conclusions can be extracted from our
results. Thus, they reinforce the advantages of the therapeutic use
of RUTIH against LTBI by adding a prophylactic effect against
future reinfections, which is a major concern when trying to
implement LTBI treatment in countries with a high risk of M.
tuberculosis infection. They also include a new potential use on those
persons with strong evidence of recent infection that have not
developed yet any specific immune response. Data demonstrate a
prophylactic effect of RUTIH which is long-lasting, thus suggesting
that it should be tested as a candidate BCG booster. Further
experiments will however be needed to determine the exact
mechanism of action of this vaccine candidate, to explore its value
in more situations and to finally establish its indications.
Materials and Methods
Different experiments were designed to evaluate any short- or
long-term prophylactic effects of the vaccine in comparison with
those triggered by BCG and to determine its effect on survival.
One experiment was design to evaluate the effect of RUTIH when
administered soon after challenge. The experimental design of the
4 experiments run is presented as Figure 5.
Figure 4. Vaccination soon after infection. The figure shows the
protection induced by vaccinating after challenge. The experimental
groups are shown as follows: black (unvaccinated animals, control
group), white (BCG day 4), horizontal striped (RUTIH day 4), diagonal
striped (RUTIH day 11) and chequered (RUTIH day 4 and 11). Significant
differences (p,0.05) respect to the control group are marked with *.
doi:10.1371/journal.pone.0020404.g004
RUTIH Prophylactic Effect against Mtb.
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RUTIH is based on detoxified fragments from M. tuberculosis
cultured under stress conditions and liposomed, manufactured by
Archivel Farma (Badalona, Catalonia, Spain) under GMP quality
standards [14]. Vaccination with RUTIH (batch B06, 260 mg) was
performed subcutaneously with two doses three weeks apart, as it
is done when administered as a therapeutic approach. BCG
vaccinated mice received a single dose of BCG Danish (SSI,
Copenhagen, Denmark; 10
6 CFUs), injected subcutaneously.
Infection
M. tuberculosis strain H37Rv Pasteur was grown in Proskauer
Beck medium. Animals were placed in the exposure chamber of an
airborne infection apparatus (Glas-col Inc., Terre Haute, IN,
USA) for infection with a low dose of M. tuberculosis. Nebulization
provided an approximate uptake of 20–50 bacilli by mice lungs
and 10 bacilli by guinea pig lungs.
Ethics
All animal procedures were approved and supervised by the
Animal Care Committee of the Germans Trias i Pujol University
Hospital and by the Department of Environment of the Catalan
Government (approval numbers 4092, 4095 and 4122). Mice and
guinea pigs were weighed and checked every day following a
protocol that monitored weight loss, apparent good health (bristled
hair and wounded skin) and behaviour (signs of aggressiveness or
isolation). Mice were euthanized with isoflurane and guinea pigs
with ketamine (100 mg/kg) plus diazepam (5 mg/kg).
Short-term prophylactic vaccination experiment.
Experimental design
6–7-week-old female C57BL mice (Harlan Iberica, Sant Feliu
de Codines, Catalonia, Spain) were used for a standard
experiment [19] (performed in duplicate) involving the aerosol
challenge of animals shortly after vaccination. Three experimental
groups were established: a) infected non-vaccinated control; b)
BCG vaccinated animals, and c) RUTIH vaccinated mice. Each
group included 12 animals.
BCG and RUTIH vaccines were administered at week 24. A
boost of RUTIH was given at week 21.
The mice were sacrificed three weeks after infection and lung
and spleen samples extracted in order to evaluate the bacillary
load.
Long-term vaccination experiment. Experimental design
6–7-week-old female C57BL mice (Harlan Iberica, Sant Feliu
de Codines, Catalonia, Spain) were used for this experiment
(performed in duplicate). Five experimental groups were estab-
lished : a) non-vaccinated control; b) BCG vaccinated animals; c)
RUTIH vaccinated mice; plus two booster groups involving: c)
BCG plus boosting with RUTIH and d) RUTIH plus boosting with
RUTIH. Each group included 12 animals.
One single dose of BCG vaccine and two of RUTIH three weeks
apart were given. Boosting with two doses of RUTIH was done in
boosted groups at both four and one weeks before challenge. All
animals were challenged by aerosol nine months after the first
vaccination. Mice were sacrificed three weeks post-infection and
lung and spleen samples extracted in order to evaluate the
bacillary load.
Short-term vaccination in guinea pigs. Experimental
design
250-g specific pathogen-free female Dunkin-Hartley guinea pigs
(Harlan Iberica, Sant Feliu de Codines, Catalonia, Spain) were
used for this experiment. Three experimental groups were
established (six guinea pigs per group): a) non-vaccinated control;
b) single dose of BCG vaccine; c) two doses of RUTIH vaccine
three weeks apart. Animals were challenged by aerosol 5 weeks
Figure 5. Experimental design of the experiments. The figure shows in 4 panels the experimental design of the 4 experiments run. As indicated
in the figure, red arrows mean RUTIH vaccination (dotted if boosting) and the blue arrow means BCG vaccination. The purple X represents endpoint
(mice sacrifice), the yellow vertical arrow the aerosol challenge and the blue horizontal arrow following-up to evaluate survival.
doi:10.1371/journal.pone.0020404.g005
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establish the effect of the vaccination on their survival. Any animal
which appeared to suffering or which suffered a 20% weight loss
was sacrificed in order to comply with all ethical requirements. A
Kaplan-Meier Survival Analysis was performed to detect any
differences between the experimental groups and determine their
statistical significance.
Protective effect in recently infected animals.
Experimental design
6–7-week-old female C57BL mice (Harlan Iberica, Sant Feliu
de Codines, Catalonia, Spain) were used for this experiment
(performed in duplicate). Animals were vaccinated shortly after
challenge (day 0): with BCG on day 4, or with RUTI on day 4, 11
or 4 and 11. The mice were sacrificed three weeks after infection
and lung and spleen samples extracted in order to evaluate the
bacillary load.
Evaluation of the bacillary load
Lungs and spleens of the animals were removed every planned
timepoint, and mechanically disrupted in order to obtain tissue
homogenates to be plated in triplicate on Becton Dickinson 7H11
Middlebrook agar (Bennex Ltd, Shannon, Ireland) and incubated
at 37uC. Viable bacteria (Colony Forming Units, CFUs) were
counted four weeks after, data being recorded as the log of the
mean number of CFUs recovered per organ. The results of the
different groups were compared and evaluated for statistically
significant differences (One Way Anova test), with the differences
being considered significant at P#0.05.
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